The Ministry of Health of Vietnam has officially promulgated Circular No. 16/2026/TT-BYT, establishing strict regulatory operations for implementing free medication support programs at medical examination and treatment facilities under the statutory framework of the national Law on Drugs. Scheduled to take legal effect on July 10, 2026, the updated administrative decree institutes a rigorous monitoring matrix designed to guarantee equitable healthcare access for patients while permanently banning commercial enterprises from exploiting these welfare channels for advertising, corporate marketing, or product promotions. The mandate excludes medications classified under non-refundable grants that are already hạch toáned within state budget revenues.
The operational baseline, structural compliance criteria, and institutional responsibilities outlined in the Circular feature:
-
Patient Stratification and Financial Architecture: Eligible recipients must be definitively diagnosed, receive a validated prescription matching the program’s verified indications, and formally participate on a voluntary basis. The volume of assistance is dictated by the logistical capacity of the pharmaceutical business rather than a mandatory obligation to supply the entirety of a patient’s therapeutic course. Programs must guarantee zero cost-sharing, contain no restrictive commercial clauses, and exert zero influence over a physician’s independent selection of rational and safe clinical regimens. For patients holding national health insurance profiles, the Social Insurance Fund is legally prohibited from reimbursing any pharmaceutical volumes supplied free of charge through the program.
-
Bilateral Contractual Obligations and Priority Groups: Healthcare facilities and pharmaceutical distributors are required to execute formal written agreements explicitly documenting the specific drug profiles, assistance methods, exact supply volumes, and definitive commencement and termination dates. The policy encourages institutions to actively prioritize support for individuals with meritorious services to the revolution, impoverished or near-poor households, ethnic minorities, the elderly, people with disabilities, children, students, social allowance recipients, laborers facing extreme hardships, and insured patients enduring heavy financial strain.
-
Dedicated Logistics and Specialized Storage Protocols: All distributed medicines must hold valid marketing authorizations in Vietnam and be utilized strictly for authorized indications and targeted patient groups. Furthermore, these supportive pharmaceutical stocks must be safely stored in separate inventory zones featuring distinct, independent labels for readily verifiable tracking.
-
Mandatory Transparency Controls for Medical Facilities: Participating hospitals are required to transparently publish all program details across corporate web portals or public notice areas. Clinical staff must provide comprehensive, timely consultations covering treatment regimens, clinical efficacy, adverse reactions, and relative cost parameters within the phác đồ. Additionally, facilities must implement tight internal controls to prevent resource waste or drug abuse, while compiling aggregate annual results to be integrated into the institution’s official year-end performance reports.
According to structural assessments from the Department of Health Insurance under the Ministry of Health, these managed support programs deliver critical socioeconomic value by directly reducing the financial burden of medical maintenance, particularly for patients combating critical, high-cost conditions such as oncological diseases.